John Mendlein steps in to help fo­cus on the big pic­ture at a fast-grow­ing Mod­er­na

Two months ago John Mendlein passed the reins at aTyr, qui­et­ly step­ping away from a com­pa­ny he had run for 6 years.

This morn­ing, he’s back in a much more vis­i­ble po­si­tion.

Stéphane Ban­cel has named Mendlein as the new com­pa­ny pres­i­dent at biotech uni­corn Mod­er­na, with re­spon­si­bil­i­ty for cor­po­rate and prod­uct strat­e­gy. It’s an un­usu­al move for a biotech like Mod­er­na, which is still nav­i­gat­ing the ear­ly stages of clin­i­cal de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.